We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Performance and Safety Evaluation of an Intradermal Delivery Device

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01359111
First Posted: May 24, 2011
Last Update Posted: May 18, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
PATH
May 2, 2011
May 24, 2011
April 16, 2012
May 11, 2012
May 18, 2012
May 2011
May 2011   (Final data collection date for primary outcome measure)
Proportion of Injections Delivered to the Intradermal Layer of the Skin [ Time Frame: 1 day ]
The proportion of saline injections via the ID Adapter resulting in delivery to the intradermal layer of the skin will be assessed by visualization of intradermal wheals with diameters ≥ 5mm, the volume of liquid injected, and confirmation of delivery to the intradermal layer by ultrasound.
Same as current
Complete list of historical versions of study NCT01359111 on ClinicalTrials.gov Archive Site
  • Proportion of Participants With Safety Events [ Time Frame: 2 days ]
    The proportion of participants with safety events will be calculated for events occurring within 30 minutes and within 48 hours of injection.
  • Proportion of Injections Administered With Needle Bevel up and Needle Bevel Down Delivered to the Intradermal Layer of the Skin. [ Time Frame: 1 day ]
    The proportion of saline injections administered with the ID Adapter with needle bevel oriented up and needle bevel oriented down resulting in delivery to the intradermal layer of the skin. This will be assessed by visualization of intradermal wheals with diameters ≥ 5mm, the volume of liquid injected, and confirmation of delivery to the intradermal layer by ultrasound.
Same as current
Not Provided
Not Provided
 
Performance and Safety Evaluation of an Intradermal Delivery Device
Phase I Performance and Safety Evaluation of an Intradermal Delivery Device
The purpose of this study is to evaluate whether an investigational vaccine delivery device (the ID adapter) can safely and precisely inject liquid into the intradermal layer of the skin.
Not Provided
Interventional
Phase 1
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Injections, Intradermal
Device: PATH ID Adapter
Intradermal delivery device which fits on the end of a syringe to limit the depth and angle of needle penetration into the skin.
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
20
May 2011
May 2011   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Female and male participants ages 18 to 55 years.
  • Healthy enough to participate in the clinical trial per site investigator assessment.
  • Healthy skin on the upper deltoid region of both arms.
  • Able to provide signed informed consent and understand study procedures per ICH/GCP guidelines.
  • Literate in English.
  • Available by telephone 48 hours after the study visit.

Exclusion Criteria:

  • Skin abnormalities on upper deltoid region of either arm (scars, rash, infection) or other skin conditions that would interfere with the ability to visualize an intradermal injection in the opinion of the investigator.
  • Unable to understand the study purpose or procedures.
Sexes Eligible for Study: All
18 Years to 55 Years   (Adult)
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT01359111
HS 563
No
Not Provided
Not Provided
PATH
PATH
Not Provided
Principal Investigator: Leslie Klaff, MD, PhD Rainier Clinical Research Center
PATH
May 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP